A woman with well-controlled oligometastatic HR+/HER2– breast cancer on endocrine + CDK4/6 therapy developed a new, localized HR+/HER2+ breast tumor that has been fully resected. How should the new HER2+ primary be treated in the context of ongoing control of her original metastatic disease?